Biomarkers have become indispensable in the creation and optimization of cutting-edge treatments.
Tuesday, February 11, 2025
To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?
Monday, February 03, 2025
To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?
Monday, February 03, 2025
To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?
Monday, February 03, 2025
To benchmark the sector’s progress in the inaugural issue of Cell & Gene Therapy Review, we asked thought leaders a single question: What is the biggest challenge facing the CGT sector in 2025?
Monday, February 03, 2025
As we head into a new year, it’s time to look back at 2024 and appreciate the tremendous progress made in cell and gene therapy.
Thursday, January 02, 2025
With a well-established infrastructure that spans the entire pharma value chain from APIs to manufacturing, Switzerland is uniquely positioned to become a specialized hub for the most promising area of advanced medicine — cell and gene therapies.
Friday, December 13, 2024
The industry stays on track with FDA approvals for cell and gene therapies
Monday, November 25, 2024
How flexible rapid testing can serve the different needs of cell and gene therapy manufacturers
Friday, November 22, 2024
By continuing to crack the code of complex manufacturing, we can move closer to making long-lasting treatments affordable and available to all
Friday, November 22, 2024